RNS Number:7339H
Celsis International PLC
31 July 2001




                                         Embargo: 7.00am, Tuesday 31 July 2001



                           CELSIS INTERNATIONAL PLC


                                AGM STATEMENT


The following is an extract from a statement made by Mr Derek Pearce, Deputy
Chairman of Celsis, at today's Annual General Meeting.

"In the report and accounts for the year ended 31 March 2001 we reported that
during the year the Board appointed a new management team to Celsis headed by
Mr Jay LeCoque, Celsis' new Chief Executive. Together with Mr Christian
Madrolle, as new Finance Director, and Dr Peter Grant as Director of
Technology and Business Development, this new team has brought strong,
hands-on experience to Celsis; to deliver the potential that Celsis has is in
the field of rapid microbial testing.

"In the last six months of the year Celsis has been restructured to correct
the lack of performance in the European dairy sector. For the first time
Celsis has now a unified global approach to sales and marketing. The final
part of Celsis' restructure followed the acquisition of ConCell in March 2001.
This acquisition not only removes a competitor, from the dairy sector, but
also provides Celsis with high performance instrumentation and reagent
technology with which to leverage its world-wide position, in the dairy
sector, going forward.

"The Global Corporate Account Management (GCAM) programme will continue to
expand Celsis' leadership position in the pharmaceutical and personal care
product sectors. Celsis continues to focus on new site implementations, as
well as the number of products tested per site, to generate increased sales
from global blue chip companies.

"The new management team have completed a review of operations, during the
second half of last year, which has resulted in the adoption of a new global
sales policy. This change has meant that Celsis has also needed to change the
revenue recognition policy for the products business. This new policy
recognises a sale when a written commitment, to implement the Celsis
technology, has been received from the customer. Previously a sale was
recognised on dispatch of an instrument. These changes mean that Celsis has a
strong base from which future growth in the business can be accurately
predicted.

"Celsis Laboratory Group (CLG) delivered exceptional results this year and
have excelled under its new management structure. CLG is determined to
continue its rapid growth by offering its customers the highest quality
standards of analysis with competitive turnaround times.

"Following the changes and restructuring made last year, Celsis is looking
forward to years of stable growth ahead".

Enquiries

Celsis International plc    Jay LeCoque, Chief Executive

Jenny Parsons, Corporate Communications   +44-1223-426008

Notes to Editors

Celsis International plc

Celsis International plc is a world leader in the development and supply of
rapid diagnostic and monitoring systems to detect and measure microbial
contamination in finished products bound for consumers. It has successfully
developed tests for use in the pharmaceutical, cosmetic and toiletries, food
and beverage industries. These tests are based upon the years of research in
enzyme technology that employ numerous methods for the rapid detection of
microbial contamination. Celsis International plc also has a leading
laboratory services company servicing the pharmaceutical and cosmetic and
toiletries industries, which operates primarily in the United States.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.